Hyderabad ( Telangana ) [ India ], March 20 ( ANI ): Bharat Biotech International Limited (BBIL), which has been at the forefront of developing and producing cost-effective domestic vaccines, unveiled today the establishment of India’s sole fully integrated, specially designed facility for Cell and Gene Therapies (CGT) along with viral vector production in Genome Valley within Hyderabad, Telangana. This expansion marks their transition into advanced regenerative and personalized treatments, offering new possibilities of hope for countless individuals, as stated in an official statement.
According to the announcement, this facility marks the beginning of a new phase in gene and cell therapy aimed at addressing key scientific issues including precise gene activation, regulation of the immune system, and sustaining cell longevity over extended periods. Their research will cover enhancing immune reactions towards cancers as well as guaranteeing the safe acceptance of therapeutic proteins in individuals suffering from conditions such as hemophilia.
The newly built 50,000-square-foot advanced CGT facility marks another significant step toward fulfilling BBIL’s enduring commitment to provide precise, lifesaving therapies for global health issues. By focusing on severe illnesses like hematologic cancers and genetic blood diseases, they aim to tackle crucial medical gaps around the world.
Detailing the objective of setting up India's sole fully integrated cellular company gene therapy facility, Dr. Krishna Ella, who serves as the Executive Chairman, Bharat Biotech , stated, "Gene and cell therapies embody some of the most complex, cutting-edge treatments we have today, encompassing elaborate procedures that demand proficiency in exact genetic manipulation and advanced manufacturing skills." Bharat Biotech With its vast experience and established expertise in viral vaccine production, this entity is well-equipped to tackle these challenges effectively. It can create high-quality vectors at the necessary volume and reliability required for clinical trials, thereby contributing significantly to the worldwide effort against uncommon and intricate illnesses."
Dr. Raches Ella, Head of Development Services, Bharat Biotech Leading this CGT project stated, "Our aim with Bharat is to make gene therapies more accessible, as they have typically been extremely costly and largely confined to developed countries or upscale facilities. The CGT center we're establishing will be geared towards generating high-titer viral vectors such as AAV, lentiviruses, and adenoviruses—vectors crucial for cellular applications." gene therapy Applications include essential materials for combating cancer and genetic disorders, along with strong capabilities in clinical development for quality control approvals.
Furthermore, it can produce a range of therapeutic products designed for different platforms targeting various conditions such as hematologic malignancies, solid tumor cancers, and genetic diseases.
Professor Krishanu Saha from the University of Wisconsin, Madison, commented, "Breakthroughs in biomanufacturing for potential cure-through cell and gene therapies come from all corners of the globe. It’s inspiring to see the skill and dedication devoted to advancing and expanding new concepts here in India, specifically at Bharat Biotech My laboratory has started an innovative partnership with Bharat Biotech To create advanced CAR (chimeric antigen receptor) cell therapies utilizing artificial intelligence for the next generation.
In the end, true advancements in product design and expansion will improve healthcare worldwide.
"For decades, Bharat Biotech Has driven India’s push towards producing cost-effective vaccines for severe illnesses. “This new CGT facility syncs with BBIL’s larger ambition of moving past conventional vaccines into the realm of personalized medicine. By harnessing our established skill in forming key international collaborations, this project will facilitate the swift conversion of cutting-edge scientific breakthroughs—from powerful therapeutic vectors to in-vivo CAR (chimeric antigen receptor) production—into practical applications,” stated Dr. Ella.
Dr. Raches elaborated on the CGT focal points aimed at addressing the needs for sophisticated disease management, stating, “Our primary emphasis lies in Oncology and the treatment of rare diseases. This establishment will facilitate an extensive range of cutting-edge therapies such as CD19 CAR T-cell therapy for blood cancers and gene therapy. By drawing from this profound knowledge base.” Bharat Biotech not only closing the gap between groundbreaking innovations and widespread accessibility but also reinforcing its long-standing dedication to making healthcare available to everyone in the country and far beyond."
Key distinguishing factors and technological advancements encompass expert partnerships, with a distinguished scientific advisory council and international research collaborators steering us toward the forefront of cutting-edge genome editing and cell production techniques. This facility is outfitted for sophisticated operations. viral vector production , aimed at generating high-titer viral vectors like AAV, Lentivirus, and Adenovirus, which are crucial for cellular applications. gene therapy applications.
A comprehensive quality assurance system has been implemented, featuring dedicated teams monitoring both initial and final stages of production to guarantee adherence to regulations and produce viral vectors that adhere to the strictest criteria for clinical applications. Moreover, the adaptable facility architecture is structured to support ongoing growth as cell and gene therapy research progresses and market needs expand.
Moreover, various specialized groups—including those focused on process development, manufacturing, quality assurance, and quality control—will work together in a single location to accelerate the clinical implementation of new treatments. The comprehensive operations are scheduled to begin once the facility secures all necessary regulatory approvals and finishes the outstanding construction stages, the statement noted. (ANI)
Post a Comment